Noah Sachs

Alkermes, Inc. develops and manufactures pharmaceutical products. It offers medicines for the treatment of central nervous system (CNS) diseases. The company was founded by Michael A. Wall, Floyd E. Bloom, Frederick W. K. Brown, Paul R. Schimmel and Alexander G. Rich in 1987 and is headquartered in Waltham, MA.

Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA.

Expressive Constructs, Inc. researches and develops antibody detection technologies. The company's products include diagnostic sensor for urinary tract infections and wound care systems that provide warning of emergent infections and promote healing. It was founded by Mitch Sanders in 1998 and is headquartered in Worcester, MA.

Reliant Pharmaceuticals, Inc. sells, markets and develops cardiovascular pharmaceutical products. The company focuses on marketing promotionally sensitive pharmaceutical products to the primary care, cardiovascular and specialist physician markets in the United States. The company is headquartered in Liberty Corner, NJ

Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers.

Wildcat Discovery Technologies, Inc. provides commercial research and development services. The firm engages in development projects for materials for other applications, including gas storage, carbon capture, thermoelectric, and structural materials. Its products include electrolyte additives such as EM1, CM1, CM2, and EM2. The company was founded by Peter G. Schultz and Robert K. Downs in 2006 and is headquartered in San Diego, CA.

Cortria Corp. operates as a clinical-stage pharmaceutical company that focuses on developing medicines to fight cardiovascular disease. Its product is used for the treatment of dyslipidemia, an atherogenic disorder characterized by abnormal lipid levels in the bloodstream. The company was founded in August 2005 and is headquartered in Needham, MA.

Inventure Renewables, Inc. provides process technologies for the extraction of mixed sugars and other value-added derivatives. It offers biofuels, biochemicals and biomaterials solurions. The company was founded by Hans Haglund and Mark G. Tegen in July 2007 and is headquartered in Tuscaloosa, AL.

AbCellera Boston, Inc. produces vaccines for plant, animal, and human diseases. It focuses on the discovery of novel therapeutics for autoimmune disease and pain. The company was founded by Theodore G. Clark in 2004 and is headquartered in Arlington, MA.

Microvi Biotech, Inc. develops clean and waste-free water treatment technologies. It offers scientifically-advanced biotechnologies available to clean water, preserve the environment, and protect human health. The firm also conducts extensive research and development programs designed to discover and implement novel solutions for a variety of environmental and human needs. The company was founded by Fatemeh Shirazi in 2004 and is headquartered in Hayward, CA.

Longwood Fund LP invests in companies located in the US. The fund targets companies operating in the fields healthcare companies. It provides financing for early stage capital requirements.

Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA.

Presidio Partners is a venture capital firm founded in the year 1989 by Thomas R. Baruch. The firm is headquartered in San Francisco, California.

Cell Signaling Technology, Inc. manufactures and distributes research tools for cell function and diseases. It offers primary antibodies, activators and inhibitors, buffers and dyes, cellsimple, and cytokines. The company was founded in 1999 and is headquartered in Danvers, MA.

Heptares Therapeutics Ltd. designs and develops new medicines targeting G protein-coupled receptors. It builts an exciting discovery and development pipeline of novel drug candidates, which have the potential to transform the treatment of serious diseases, including alzheimer's disease, parkinson's disease, schizophrenia, migraine and diabetes. The company was founded by Richard Henderson, Fiona Hamilton Marshall, Ludwig Michael Steinmetz, Christopher G. Tate and Malcolm Weir in 2007 and is headquartered in Welwyn Garden City, the United Kingdom.

Toxikon Corp. provides life science and laboratory services. The firm's services include toxicology, chronic, reproductive and chronic toxicity, genetic toxicology, carcinogenicity, pharmacokinetics, toxicokinetics, and microbiology. It offers services to the pharmaceutical, medical devices, and drug companies. The company was founded in 1977 and is located in Bedford, MA.

The National Health Council provides united voice for people with chronic diseases and disabilities and their family caregivers. The company was founded in 1920 and is headquartered in Washington, DC.

Longwood Fund Management LLC (Longwood Fund) is a venture capital firm founded in 2010 by Christoph H. Westphal, Michelle Detwiler and Richard H. Aldrich. The firm is headquartered in Boston, Massachusetts.

Theriana Pharmaceuticals, Inc. provides pharmaceutical services. The company was founded in 2017 and is headquartered in Waltham, MA.

Avilar Therapeutics is an American biopharmaceutical company that specializes in the discovery and development of extracellular protein degraders. The company is based in an undisclosed location. The company has developed a proprietary discovery platform that includes novel, high-affinity, small molecule asgpr ligands and advanced modeling of the biophysics, pharmacokinetics, and pharmacodynamics of atac mediated endocytosis and degradation. Avilar is developing atacs, a new class of protein degraders that shuttle disease-causing proteins from circulation to the endolysosome where the unwanted proteins are degraded. The company is leveraging their atac platform to create a broad and diverse pipeline of first-in-class extracellular protein degraders. The company was founded by Nathaniel Brooks Horwitz and Jamie Kasuboski. The CEO is Daniel S. Grau.

Lusaris Therapeutics, Inc. is a biotechnology company that focuses on developing next-generation serotonergic neuroplastogen therapeutics to treat severe neuropsychiatric and neurological disorders. The company is based in Boston, MA. The company's lead program, LSR-1019, is a proprietary sublingual formulation of 5-MeO-DMT, a rapidly acting and rapidly clearing serotonergic psychedelic, which is being developed to treat treatment-resistant depression and other neuropsychiatric conditions. The company's pipeline also includes novel neuroplastogens for a wide range of neuropsychiatric and neurological conditions, including migraine and cluster headache. The CEO of the company is Andrew D. Levin.